Monday, October 26, 2026

Fed Rate Cycle Drove Equity Valuations Down 25% in 2022, Then Back Up 60% as Cuts Began

The Federal Reserve's aggressive rate hikes from March 2022 to mid-2023 drove the S&P 500 down 25% as discount rates soared and bond yields hit 5%. The subsequent cutting cycle starting September 2024 reversed equity losses, with stocks rallying 60% from lows as 10-year Treasury yields fell below 4% by January 2026.

Fed Rate Cycle Drove Equity Valuations Down 25% in 2022, Then Back Up 60% as Cuts Began
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The Federal Reserve's most aggressive rate hiking cycle since the 1980s triggered a dramatic repricing across asset classes. Rates rose from near-zero in March 2022 to peak levels by mid-2023, sending the S&P 500 down 25% in 2022 as higher discount rates compressed equity valuations.

Bond yields surged to 5% on 10-year Treasuries during the tightening phase, marking the highest levels in 16 years. The yield spike made fixed income attractive relative to equities, pulling capital from stocks. Growth stocks with long-duration cash flows saw the steepest declines, with the Nasdaq falling 33% in 2022.

Rate-sensitive sectors faced immediate pressure. Mortgage rates exceeded 8% for the first time since 2000, freezing housing transactions. Manufacturing contracted for 26 consecutive months as financing costs rose. The trucking industry entered a recession as freight demand collapsed under higher borrowing costs.

The Fed maintained restrictive policy through early 2024 before initiating cuts in September 2024. This pivot marked a turning point for markets. Equities rallied 60% from October 2022 lows as the Fed reduced rates to 3.5-3.75% by January 2026.

Bond yields fell in response to rate cuts, with 10-year Treasuries dropping below 4% by early 2026. The yield curve normalized after prolonged inversion, signaling improved economic outlook. Credit spreads tightened as financial conditions eased.

Trading dynamics shifted dramatically between cycles. During tightening, defensive sectors outperformed as investors sought stability. Utilities and consumer staples led gains. The easing cycle reversed this pattern, with technology and cyclical sectors reclaiming leadership as growth became affordable again.

Options markets reflected the volatility. VIX spiked above 30 during tightening phases as uncertainty peaked. Put-call ratios stayed elevated through 2023. As cuts began, volatility collapsed to 15, indicating renewed confidence.

The rate cycle exposed the sensitivity of modern portfolios to monetary policy. The 60/40 stock-bond allocation posted its worst year in 2022, with both assets falling simultaneously. Recovery required the Fed's policy shift to realign asset prices with fundamentals.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· February 2, 2026
    Kevin Warsh’s Fed Will End the War on Main Street and Trucking

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com